Description
Indication & Scope
Oxaliplatin for Injction (Eloxatin®), 3rd-gen DACH platinum chemo, crosslinks tumor DNA to suppress replication and trigger apoptosis. It has minimal renal/ototoxicity, superior anti-colorectal activity and distinctive cold-induced neuropathy vs cisplatin/carboplatin.
- Mechanism
Form intra/interstrand cross-link with tumor DNA, inhibit DNA synthesis and tumor cell proliferation - Drug class
Third-generation platinum-based cytotoxic chemotherapeutic agent - Clinical use
Stage III colon cancer adjuvant therapy, metastatic colorectal cancer, advanced gastric cancer
| Generic Name | Oxaliplatin for Injction |
| Brand Name | Eloxatin® |
| Ingredient | Oxaliplatin |
| Dosage Form | Injection |
| Package | 50mg/vial |
| Conditions Treated | Adjuvant therapy for Stage III colon cancer after radical resection of primary tumor, combined with 5-FU & leucovorin; First-line treatment of metastatic colorectal cancer (mCRC) in combination with fluoropyrimidines; Combined chemotherapy for advanced gastric cancer |
| Taboos | Hypersensitivity to oxaliplatin or any platinum anti-tumor drugs; severe renal insufficiency; pregnant & lactating women |
| Place of origin | Braine-L’Alleud, Belgium |
| Priscription Type | Prescription drug (Rx) |
| Storage Conditions | Seal tightly, store below 25℃, protect from cold stimulation after reconstitution |
| Manufacturer | CENEXI-Laboratoires THISSE S.A. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | HJ20171065 |
| Date of Approval | December 11, 2023 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: 85mg/m² iv infusion over 2 hours, once every 2 weeks; adjuvant treatment for up to 12 cycles; metastatic patients use until disease progression or intolerable toxicity; dilute only with 5% glucose injection, infuse before fluoropyrimidines
Time: Biweekly chemotherapy cycle; avoid cold food, cold water and cold contact during treatment
Interaction: Incompatible with normal saline & alkaline solution (5-FU); synergistic anti-tumor effect with fluoropyrimidines
Side effects: Cold-induced peripheral sensory neuropathy (dose-limiting toxicity), mild myelosuppression, nausea/vomiting, hypersensitivity reactions, liver sinusoidal injury
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is its typical dose-limiting adverse reaction?
Cold-induced peripheral sensory neuropathy.
Can oxaliplatin be mixed with 0.9% sodium chloride?
No, chemical precipitation will occur.
What is the core advantage over cisplatin?
Almost no nephrotoxicity, better efficacy for gastrointestinal tumors.
Who cannot receive Eloxatin treatment?
Patients allergic to platinum drugs, severe renal dysfunction, pregnant women.
Eloxatin® | Oxaliplatin for Injction | Stage III Colon Cancer,MCRC and AGC | DengYueRX
INN: Oxaliplatin
Indications: Stage III Colon Cancer,MCRC (metastatic colorectal cancer) and AGC (advanced gastric cancer)
Dosage Form: Injection
Strength: 50mg/Vial
Original price was: $443.70.$377.14Current price is: $377.14.
